

ASCO 2018 investor event; breakout 2: *Lynparza* lifecycle; MRK collaboration

**Klaus Edvardsen, Senior Vice President,
Head of Oncology, Global Medicines Development**

04 June 2018



Forward-looking statements

In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act 1995, we are providing the following cautionary statement: This document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although we believe our expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and AstraZeneca undertakes no obligation to update these forward-looking statements. We identify the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond our control, include, among other things: the loss or expiration of, or limitations to, patents, marketing exclusivity or trademarks, or the risk of failure to obtain and enforce patent protection; effects of patent litigation in respect of IP rights; the impact of any delays in the manufacturing, distribution and sale of any of our products; the impact of any failure by third parties to supply materials or services; the risk of failure of outsourcing; the risks associated with manufacturing biologics; the risk that R&D will not yield new products that achieve commercial success; the risk of delay to new product launches; the risk that new products do not perform as we expect; the risk that strategic alliances and acquisitions, including licensing and collaborations, will be unsuccessful; the risks from pressures resulting from generic competition; the impact of competition, price controls and price reductions; the risks associated with developing our business in emerging markets; the risk of illegal trade in our products; the difficulties of obtaining and maintaining regulatory approvals for products; the risk that regulatory approval processes for biosimilars could have an adverse effect on future commercial prospects; the risk of failure to successfully implement planned cost reduction measures through productivity initiatives and restructuring programmes; the risk of failure of critical processes affecting business continuity; economic, regulatory and political pressures to limit or reduce the cost of our products; failure to achieve strategic priorities or to meet targets or expectations; the risk of substantial adverse litigation/government investigation claims and insufficient insurance coverage; the risk of substantial product liability claims; the risk of failure to adhere to applicable laws, rules and regulations; the risk of failure to adhere to applicable laws, rules and regulations relating to anti-competitive behaviour; the impact of increasing implementation and enforcement of more stringent anti-bribery and anti-corruption legislation; taxation risks; exchange rate fluctuations; the risk of an adverse impact of a sustained economic downturn; political and socio-economic conditions; the risk of environmental liabilities; the risk of occupational health and safety liabilities; the risk associated with pensions liabilities; the impact of failing to attract and retain key personnel and to successfully engage with our employees; the risk of misuse of social medial platforms and new technology; and the risk of failure of information technology and cybercrime. Nothing in this presentation / webcast should be construed as a profit forecast.




Lynparza: ovarian cancer

Full development programme across lines of treatment




Study 19: impressive survival in all-comer 3rd-line+ patients




0.62
Hazard ratio

SOLO-2: progression-free survival in BRCAm 2nd line



19.1 months
Investigator-assessed
progression-free survival

SOLO-1: BRCAm 1st-line patients



* As per RECIST and provided that the patient does not meet any other discontinuation criteria. Patients should continue with trial treatment until RECIST progression, despite rises in CA-125. In SOLO-1, patients with evidence of stable disease after two years may continue to receive trial treatment if, in the opinion of the investigator, it is in the interest of the patient. If, after two years, the patient has no evidence of disease, trial treatment should be discontinued.



Source: ASCO 2016, abstract 5501.


Source: SGO 2017, 2 - Late Breaking Abstract.

Lynparza: breast cancer

Extending benefit into an additional tumour type




OlympiAD: reduced the risk of disease progression or death by 42% compared to standard of care



H2 2018: regulatory decision (JP)
2019: regulatory decision (EU)

OlympiA: adjuvant treatment in gBRCAm high-risk HER2-negative primary breast cancer



2021: Phase III data readout

Source: ASCO 2017, abstract LBA4.




Lynparza: prostate cancer

PARP inhibition beyond ovarian and metastatic breast cancers




Study 08: Lynparza with abiraterone in treating 2nd-line metastatic castration resistant prostate cancer



Phase III trial based on the results is planned

PROfound Phase III in metastatic castration-resistant prostate cancer HRRm¹ (post abiraterone/enzalutamide)



2019+ Phase III data readout

Source: ASCO 2018, abstract 5003.

1. Homologous recombination repair mutation.



Lynparza: IO combinations

Significant opportunity to further expand through Merck collaboration



Key Lynparza combination trials

DuO-O, Phase III (*Lynparza* + *Imfinzi*)

- Advanced, 1st-line ovarian cancer

BAYOU, Phase II (*Lynparza* + *Imfinzi* vs. *Imfinzi*)

- Phase II, Stage IV, 1st-line cis-platinum chemotherapy-ineligible urothelial bladder cancer

MEDIOLA, Phase I/II basket trial (*Lynparza* + *Imfinzi*)

- Advanced, 2nd-line g*BRCA*-mutated ovarian cancer
- Stage IV, 1st to 3rd-line g*BRCA*-mutated, HER2-negative breast cancer
- Stage IV, 2nd-line small cell lung cancer (SCLC)
- Stage IV, 2nd-line gastric cancer

Development status of Merck collaboration



- Collaboration infrastructure set up and agreed
- Joint steering committee and sub teams created
- Increasing number of new joint programmes
- Development plans agreed for priority programmes
- Maximising the potential of *Imfinzi* and Keytruda as leading IO early- and late-stage lung cancer medicines



Q&A



Use of AstraZeneca conference call, webcast and presentation slides

The AstraZeneca webcast, conference call and presentation slides (together the 'AstraZeneca Materials') are for your personal, non-commercial use only. You may not copy, reproduce, republish, post, broadcast, transmit, make available to the public, sell or otherwise reuse or commercialise the AstraZeneca Materials in any way. You may not edit, alter, adapt or add to the AstraZeneca Materials in any way, nor combine the AstraZeneca Materials with any other material. You may not download or use the AstraZeneca Materials for the purpose of promoting, advertising, endorsing or implying any connection between you (or any third party) and us, our agents or employees, or any contributors to the AstraZeneca Materials. You may not use the AstraZeneca Materials in any way that could bring our name or that of any Affiliate into disrepute or otherwise cause any loss or damage to us or any Affiliate. AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA. Telephone + 44 20 3749 5000, www.astrazeneca.com

